Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
influenza vaccine
Biotech
GSK plans phase 3 after mRNA flu vaccine beats standard shots
GSK linked its mRNA seasonal flu vaccine to higher immune responses than conventional jabs, emboldening the company to start a pivotal study.
Nick Paul Taylor
Sep 1, 2026 5:43am
Osivax bags flu vaccine rights to pursue combination shot vision
Aug 27, 2026 10:00am
FDA appears less prickly toward Moderna mRNA flu shot
Jun 16, 2026 2:46pm
FDA accepts filing for Moderna flu vaccine after swift rethink
Feb 18, 2026 9:21am
Moderna hit with FDA refusal-to-file letter for mRNA flu shot
Feb 10, 2026 7:45pm
CEPI to fund Moderna's pandemic flu trial after HHS walked away
Dec 18, 2025 9:40am
